Advanced search
Publication Cover
International Journal of Hyperthermia Volume 34, 2018 - Issue 5
Submit an article Journal homepage
1,076
Views
7
CrossRef citations to date
0
Altmetric
Original Articles

Residual tumour less than 0.25 centimetres and positive lymph nodes are risk factors for early relapse in recurrent ovarian peritoneal carcinomatosis treated with cytoreductive surgery, HIPEC and systemic chemotherapy

Alvaro Arjona-SanchezOncologic and Pancreatic Surgery Unit, University Hospital Reina Sofía, Córdoba, Spain; ;Maimonides Biomedical Research Institute of Córdoba (IMIBIC), University Hospital Reina Sofía, University of Córdoba, Córdoba, SpainCorrespondence[email protected]
,
Sebastian Rufian-PeñaOncologic and Pancreatic Surgery Unit, University Hospital Reina Sofía, Córdoba, Spain; ;Maimonides Biomedical Research Institute of Córdoba (IMIBIC), University Hospital Reina Sofía, University of Córdoba, Córdoba, Spain
,
Manuel ArtilesOncologic and Pancreatic Surgery Unit, University Hospital Reina Sofía, Córdoba, Spain;
,
Juan Manuel Sánchez-HidalgoOncologic and Pancreatic Surgery Unit, University Hospital Reina Sofía, Córdoba, Spain; ;Maimonides Biomedical Research Institute of Córdoba (IMIBIC), University Hospital Reina Sofía, University of Córdoba, Córdoba, Spain
,
Ángela Casado-AdamOncologic and Pancreatic Surgery Unit, University Hospital Reina Sofía, Córdoba, Spain; ;Maimonides Biomedical Research Institute of Córdoba (IMIBIC), University Hospital Reina Sofía, University of Córdoba, Córdoba, Spain
,
Antonio CosanoOncologic and Pancreatic Surgery Unit, University Hospital Reina Sofía, Córdoba, Spain;
,
Heather ThoeleckeOncologic and Pancreatic Surgery Unit, University Hospital Reina Sofía, Córdoba, Spain;
,
Sharmila RamnarineOncologic and Pancreatic Surgery Unit, University Hospital Reina Sofía, Córdoba, Spain;
,
Dimas GarcilazoOncologic and Pancreatic Surgery Unit, University Hospital Reina Sofía, Córdoba, Spain;
&
Javier Briceño-DelgadoOncologic and Pancreatic Surgery Unit, University Hospital Reina Sofía, Córdoba, Spain; ;Maimonides Biomedical Research Institute of Córdoba (IMIBIC), University Hospital Reina Sofía, University of Córdoba, Córdoba, Spain
 show all
Pages 570-577 | Received 08 Jul 2017, Accepted 01 Jan 2018, Published online: 17 Jan 2018

References

  • Jemal A, Siegel R, Ward E, et al. (2007). Cancer statistics, 2007. CA Cancer J Clin 57:43–66.
  • Muñoz-Casares FC, Rufián S, Rubio MJ, et al. (2007). Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals. Clin Transl Oncol 9:652–62.
  • Ledermann JA, Raja FA, Fotopoulou C, et al. (2013). Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(suppl 6):vi24–32.
  • Siegel RL, Miller KD, Jemal A. (2015). Cancer statistics, 2015: Cancer statistics, 2015. CA Cancer J Clin 65:5–29.
  • Ozols RF. (2005). Treatment goals in ovarian cancer. Int J Gynecol Cancer 15:3–11.
  • Sugarbaker PH. (1995). Peritonectomy procedures. Ann Surg 221:29–42.
  • Sugarbaker PH. (1998). Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 14:254–61.
  • Spiliotis J, Halkia E, Lianos E, et al. (2015). Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22:1570–5.
  • Huo YR, Richards A, Liauw W, Morris DL. (2015). Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol 41:1578–89.
  • Arjona-Sanchez A, Rufián-Peña S. (2017). Progress in the management of primary and recurrent ovarian carcinomatosis with peritonectomy procedure and HIPEC in a high volume center. Int J Hyperthermia 33:554–61.
  • Muñoz-Casares FC, Medina-Fernández FJ, Arjona-Sánchez á, et al. (2016). Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: long-term outcomes and perspectives from a high-volume center. Eur J Surg Oncol 42:224–33.
  • Arjona-Sánchez A, Cadenas-Febres A, Cabrera-Bermon J, et al. (2016). “Assessment of RIFLE and AKIN criteria to define acute renal dysfunction for HIPEC procedures for ovarian and non ovarian peritoneal malignances”. Eur J Surg Oncol 42:869–76.
  • McGuire WP, Hoskins WJ, Brady MF, et al. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1–6.
  • Bristow RE, Tomacruz RS, Armstrong DK, et al. (2002). Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–59.
  • Rufián S, Muñoz-Casares FC, Briceño J, et al. (2006). Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 94:316–24.
  • Sugarbaker PH. (1996). Complete parietal and visceral peritonectomy of the pelvis for advanced primary and recurrent ovarian cancer. Cancer Treat Res 81:75–87.
  • Jacquet P, Sugarbaker PH. (1996). Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359–74.
  • Hoskins WJ, McGuire WP, Brady MF, et al. (1994). The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170:974–80.
  • Harter P, Bois A, du Hahmann M, et al. (2006). Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. Ann Surg Oncol 13:1702–10.
  • Medina Fernández FJ, Muñoz-Casares FC, Arjona-Sánchez A, et al. (2015). Postoperative time course and utility of inflammatory markers in patients with ovarian peritoneal carcinomatosis treated with neoadjuvant chemotherapy, cytoreductive surgery, and HIPEC. Ann Surg Oncol 22:1332–40.
  • Simkens GA, van Oudheusden TR, Luyer MD, et al. (2015). Serious postoperative complications affect early recurrence after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis. Ann Surg Oncol 22:2656–62.
  • Berek JS. (2009). Lymph node-positive stage IIIC ovarian cancer: a separate entity? Int J Gynecol Cancer 19(Suppl 2):S18–S20.
  • Vergote IB, Van Nieuwenhuysen E, Vanderstichele A. (2016). How to select neoadjuvant chemotherapy or primary debulking surgery in patients with stage IIIC or IV ovarian carcinoma. J Clin Oncol 34:3827–8.
  • Aletti GD, Long HJ, Podratz KC, Cliby WA. (2007). Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer? Gynecol Oncol 104:212–16.
  • Amato A, Pescatori M. (2006). Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev (1):CD005033. doi: 10.1002/14651858.CD005033.pub2

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.